JMP Securities analyst Silvan Tuerkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $86 price target.
Clear
All
Quotes
News
Learn
Help
All
US
HK
CN
SG
AU
JP
All
News
Announcements
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
JMP Securities Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Like
Views 361
Write a comment
Comment(0)
Reason For Report